For the quarter ended June 2024, Neurocrine Biosciences (NBIX) reported revenue of $590.2 million, up 30.4% over the same period last year. EPS came in at $0.63, compared to $0.95 in the year-ago quarter. The reported revenue represents a surprise of +7.56% over the Zacks Consensus Estimate of $548.7 million. With the consensus EPS estimate being $1.15, the EPS surprise was -45.22%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to d ...

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.63 per share, missing the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $0.95 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -45.22%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $1.04 per share when it actually produced earnings of $0.42, delivering a surprise of -59.62%. Over the las ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |-------|-------------------------------------------------------------|--------------------------------------------------------------------------------------------- ...

Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance ® INGREZZA (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% YearOver-Year Growth INGREZZA (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion ® Top-Line Phase 2 Data Readouts for NBI-'568 and Luvadaxistat Remain On Track in Q3 SAN DIEGO, August 1, 2024 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial resul ...

INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% YearOver-Year Growth Three Months Ended Six Months Ended INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion Top-Line Phase 2 Data Readouts for NBI-'568 and Luvadaxistat Remain On Track in Q3 SAN DIEGO, Aug. 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2024 and provided an update on its ...

The upcoming report from Neurocrine Biosciences (NBIX) is expected to reveal quarterly earnings of $1.15 per share, indicating an increase of 21.1% compared to the year-ago period. Analysts forecast revenues of $548.7 million, representing an increase of 21.2% year over year. Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has ...

The market expects Neurocrine Biosciences (NBIX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...

English check-icon Italiano Deutsch Français FX Empire Logo Español Português العربية Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial ...

"Only INGREZZA offers a sprinkle formulation to ease administration for individuals living with tardive dyskinesia or Huntington's disease chorea, who often have difficulty swallowing pills," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "We wanted to provide this new option to patients and their caregivers who want the benefit of treatment with INGREZZA without the challenge of swallowing a capsule." INGREZZA and INGREZZA SPRINKLE offer simple dosing that's always one capsule, ...

Conference Call and Webcast Scheduled for Thursday, August 1 The schedule for the press release and conference call / webcast is as follows: The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple pu ...